Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Free Cash Flow (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Free Cash Flow for 4 consecutive years, with -$2.0 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 85.47% to -$2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$49.1 million through Dec 2025, up 3.37% year-over-year, with the annual reading at -$49.1 million for FY2025, 3.37% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$2.0 million at Orchestra BioMed Holdings, up from -$14.9 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$2.0 million in Q4 2025, with the low at -$16.7 million in Q1 2025.
  • Average Free Cash Flow over 4 years is -$11.0 million, with a median of -$10.7 million recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 168.4% in 2023, then soared 85.47% in 2025.
  • Over 4 years, Free Cash Flow stood at -$8.8 million in 2022, then fell by 24.7% to -$11.0 million in 2023, then fell by 24.36% to -$13.6 million in 2024, then skyrocketed by 85.47% to -$2.0 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$2.0 million, -$14.9 million, and -$15.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.